Your browser doesn't support javascript.
loading
2022 revised European recommendations for the coding of the basis of diagnosis of cancer cases in population-based cancer registries.
Visser, Otto; Koscianska, Beata; Caetano Dos Santos, Florentino Luciano; Cuccaro, Francesco; Forjaz, Gonçalo; Michalek, Irmina Maria; Mousavi, Mohsen; Sulkowska, Urszula; Martos, Carmen; Giusti, Francesco.
Affiliation
  • Visser O; Department of Registration, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands.
  • Koscianska B; Lublin Cancer Registry, Lublin, Poland.
  • Caetano Dos Santos FL; Polish National Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Cuccaro F; Cancer Registry of Puglia, Section of Health Local Unit Barletta-Andria-Trani, Barletta, Italy.
  • Forjaz G; Westat, Rockville, MD, United States.
  • Michalek IM; Polish National Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Mousavi M; Graubünden and Glarus Cancer Registry, Chur, Switzerland.
  • Sulkowska U; Mazowiecki Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Martos C; European Commission, Joint Research Centre, Ispra, Italy.
  • Giusti F; European Commission, Joint Research Centre, Ispra, Italy.
Front Oncol ; 13: 1250549, 2023.
Article in En | MEDLINE | ID: mdl-38162487
ABSTRACT
The basis of diagnosis recommendations for population-based cancer registries aim to provide a standardized coding tool that reflects the certainty of cancer diagnosis, especially when pathological confirmation is lacking. The proportion of clinical diagnoses serves as an indicator of data quality. Given the evolving nature of diagnostic techniques, regular revision of the basis of diagnosis rules is crucial. To address this, a working group comprising representatives from the steering committee and member registries of the European Network of Cancer Registries was established. The original 1999 recommendations were comprehensively reviewed, resulting in the publication of an updated version. These new recommendations came into effect for incident cancer cases starting from January 1, 2023. The updated recommendations comprise an adapted code list for the basis of diagnosis, optional codes for histology cases, revisions related to flow cytometry, liquid biopsy, and cytogenetic/molecular testing, consolidation of histology codes 6 and 7, introduction of a new code 8 for cytogenetic/molecular confirmation, and establishment of new criteria for registering specific morphology codes in cancers lacking pathological confirmation.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Guideline Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Guideline Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: Country of publication: